Finance

Lists
688621:SHA
Beijing Sun-Novo Pharma Research Co Ltd
CN¥71.00
+0.07%
(+0.050) 1D
Sep 30, 3:00:02 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 688621...
Open
CN¥70.65
High
CN¥72.25
Low
CN¥69.60
Mkt. cap
7.95B
Avg. vol.
3.31M
Volume
1.54M
Dividend
0.26%
Quarterly dividend
CN¥0.05
Ex-dividend date
Jun 29, 2026
P/E ratio
157.09
52-wk high
CN¥80.70
52-wk low
CN¥46.68
EPS
CN¥0.45
No. of employees
1K
Open
CN¥70.65
High
CN¥72.25
Low
CN¥69.60
Mkt. cap
7.95B
Avg. vol.
3.31M
Volume
1.54M
Dividend
0.26%
Quarterly dividend
CN¥0.05
Ex-dividend date
Jun 29, 2026
P/E ratio
157.09
52-wk high
CN¥80.70
52-wk low
CN¥46.68
EPS
CN¥0.45
No. of employees
1K
News stories
From web sources and news partners
About Beijing Sun-Novo Pharma Research Co Ltd
CEO-
Employees1.1K
FoundedMar 9, 2009
Headquarters-
SectorHealth care
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
265.46M
366.49M
197.10M
229.04M
Cost of goods sold
135.95M
139.30M
99.84M
116.68M
Cost of revenue
135.95M
139.30M
99.84M
116.68M
Research and development expenses
39.26M
46.03M
35.49M
52.04M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
43.69M
81.17M
51.20M
48.29M
Operating expense
83.78M
196.54M
82.29M
169.82M
Total operating expenses
219.74M
335.85M
182.13M
286.50M
Operating income
45.73M
30.64M
14.97M
-57.46M
Other non operating income
515.48K
-2.90M
-1.15M
676.87K
EBT including unusual items
32.02M
40.77M
16.44M
-65.28M
EBT excluding unusual items
43.58M
27.67M
11.20M
-60.23M
Income tax expense
-3.04M
-5.47M
-1.99M
-18.51M
Effective tax rate
-9.49%
-13.41%
-12.11%
28.35%
Other operating expenses
-14.37M
15.66M
-1.92M
2.24M
Net income
33.45M
40.58M
20.63M
-45.03M
Net profit margin
12.60%
11.07%
10.47%
-19.66%
Earnings per share
-
-
-
-
Interest and investment income
1.77M
4.10M
759.68K
201.29K
Interest expense
-4.43M
-4.17M
-3.37M
-3.64M
Net interest expenses
-2.67M
-76.12K
-2.61M
-3.44M
Depreciation and amortization charges
-
-
-
-
EBITDA
52.07M
37.11M
21.44M
-51.05M
Gain or loss from assets sale
-359.29K
-645.20K
-
689.99K
AI content may include mistakes. Learn more
Google apps